Veterinary Renal Disease Market Size, Share & Trends Analysis Report By Type, By Animal Type (Canine, Feline, Bovine, Equine, Others), By Route of Administration, By Indication, By Distribution Channel, By Region, And Segment Forecasts, 2024 - 2030

Veterinary Renal Disease Market Size, Share & Trends Analysis Report By Type, By Animal Type (Canine, Feline, Bovine, Equine, Others), By Route of Administration, By Indication, By Distribution Channel, By Region, And Segment Forecasts, 2024 - 2030

Veterinary Renal Disease Market Growth & Trends

The global veterinary renal disease market size is anticipated to reach USD 22.90 billion by 2030 and it is projected to grow at a CAGR of 5.49% from 2024 to 2030, according to a new report by Grand View Research, Inc. Rising prevalence of renal diseases coupled with adoption of therapeutic food as a treatment are key growth drivers for this market. Renal diseases like chronic kidney disease (CKD), renal failure, etc. cause irreversible damage to the renal system of animals. Despite no definite cure for this disease, proper management by various types of therapies can help in the betterment of animal life. One of the most prominent methods is that of nutritional management through therapeutic food.

Another crucial market propeller is the rising adoption of AI in veterinary renal disease diagnostics and treatment. Imaging plays a significant role in veterinary medicine by offering vital data for regular preventative measures as well as the assessment of disease and injury. AI can prove to be a very beneficial tool, especially in radiologist deficient geographies. Associated benefits such as faster and enhanced diagnostic capabilities is anticipated to increase adoption of AI and thereby influence positively on market in near future.

Mars Inc, which is a prominent player in the animal health space, has already stepped into the field of applying AI to veterinary diagnostics and treatment. Antech Diagnostics (Mars Inc.) introduced RenalTech, a cutting-edge diagnostic tool, in 2019. RenalTech uses artificial intelligence (AI) to evaluate pet medical record data and forecast a cat's risk of developing chronic kidney disease (CKD) up to two years ahead of an established clinical diagnosis.

Moreover, market dynamics such as product portfolio expansion, M&A, consolidation activities are further anticipated to provide growth platform to this market. For example, in September 2023, Elanco Animal Health received conditional U.S. FDA approval for Varenzin-CA1 (molidustat oral suspension), as the treatment to control non-regenerative anemia in cats with chronic kidney disease (CKD). Furthermore , in December 2023, Neogen Corporation partnered with the TerraNova Equestrian Center in Myakka City, Florida, making the company the official biosecurity provider of the facility for diagnostic testing products.

Veterinary Renal Disease Market Report Highlights

• Based on type, the treatment segment led the market with the largest revenue share of 68.99% in 2023, due to the wide array of treatments available coupled with ever growing population of pets globally
• Based on animal type, the feline segment is expected to grow at the fastest CAGR over the forecast period
• Based on route of administration, the oral segment held the largest revenue share in 2023 and the injectable segment is expected to have the fastest CAGR over the forecast period
• Based on the indication, the renal cystitis segment held the largest revenue share of 29.74% in 2023 and nephritis segment is expected to have the second fastest CAGR over the forecast period
• Rising prevalence of a variety of renal complications in animals, prominent usage of pet food, growing disease awareness initiatives are contributing to the market growth
• North America accounted for the largest revenue share of the market in 2023. The increasing significance of animal health care in general throughout the region has been identified as a key factor propelling market expansion. The American Pet Products Association estimates that 65.1 million homes in the country have pets in 2023–2024. Moreover, growing pet owners' awareness of animal health and the significance of providing care for animals with renal disorders are fueling the market expansion in North America
• In May 2023, Dechra Pharmaceuticals announced distribution rights of two products to support kidney health in senior cats - Porus One, and Add One. Porus One contains renaltec, a selective absorber that soaks up precursors of uremia toxins in the cat’s intestines that would ordinarily be removed or regulated by healthy kidneys. Add One is a moist cat treat designed for senior cats, developed to encourage them to eat Porus One, and is said to be useful for cats that prefer dry food

Please note The report will be delivered in 2-3 business days upon order notification.